Assessment for Zika Virus Infection

- **For pregnant women who have a fetus with prenatal ultrasound findings consistent with congenital Zika virus infection, and who live in or have traveled to an area with ongoing Zika virus transmission, refer to [www.cdc.gov/zika/hc-providers/testing-guidance.html](http://www.cdc.gov/zika/hc-providers/testing-guidance.html) for further guidance.**

- **Zika virus IgM testing is not routinely recommended due to the long term persistence of antibodies following infection.**

---

**For individuals with possible exposure to Zika virus through travel to region with Zika transmission or possible sexual exposure:**

- **Is the patient pregnant?**
  - **YES**
    - **Evaluate for signs and symptoms of Zika virus disease (eg, fever, conjunctivitis, rash, arthralgia)**
  - **NO**
    - Testing not indicated. Consider testing for dengue virus if indicated.

- **Symptomatic**
  - Up to 12 weeks post-symptom onset
    - **Zika virus rRT-PCR (Paired serum and urine)**
      - **RZIKS / Zika Virus, PCR, Molecular Detection, Serum**
      - **RZIKU / Zika Virus, PCR, Molecular Detection, Random, Urine**
      - **DENGM / Dengue Virus Antibody, IgG and IgM, Serum**
      - One or both of the following viral markers
        - **DNSAG / Dengue NS1 Antigen, Serum**
        - **DENGs / Dengue Virus, Molecular Detection, PCR, Serum**

- **Asymptomatic**
  - Testing not indicated

---

**Positive Zika virus rRT-PCR (serum and/or urine)**
- **Acute Zika infection**
- **No evidence of Zika virus infection**

**Negative rRT-PCR and negative Zika IgM**
- **Recent dengue virus infection**
- **No evidence of Zika virus infection**

**Positive dengue IgM and/or NS1 antigen and/or dengue PCR**
- **No dengue virus infection**

© Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. 02/2021